Algernon Pharmaceuticals Inc AGNPF

Primary Symbol: C.AGN

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by yopmemama021on Dec 05, 2022 6:13pm

132 Views

Post# 35152145

AGN

big day for AGN.c shot up 22.3% on news :

just received U.S. FDA Orphan drug designation for their IPF treatment ( Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis and chronic cough)

this follows the completion of a Phase 2a study that found significant improvements in cough frequency + cough severity &quality of life

major milestone here- watching throughout their development with only 2.39M OS

https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/169/algernon-pharmaceuticals-receives-u-s-fda-orphan-drug